The chronic disease management platform has attracted pharmaceutical firm Merck as an investor and increased its total funding to more than $22m.

US-based patient management software developer CareSync raised $18m in a series B round yesterday that included pharmaceutical company Merck’s Global Health Innovation Fund.

The series B consortium also featured Greycroft Partners, Harbert Venture Partners, Tullis Health Investors, Clearwell Group, CDH Solutions and Travis Bond, the founder and chief executive of CareSync.

Founded in 2011, CareSync has built a turnkey chronic disease management platform that captures, organises and shares relevant health data with patients, family, caregivers and healthcare professionals.

The series…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?